Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy
Authors
Pelly, Victoria SMoeini, Agrin
Roelofsen, L. M.
Bonavita, Eduardo
Bell, Charlotte R
Hutton, Colin
Blanco-Gomez, Adrian
Banyard, Antonia
Bromley, Christian P
Flanagan, Eimear
Chiang, Shih-Chieh
Jorgensen, Claus
Schumacher, T. N.
Thommen, D
Zelenay, Santiago
Affiliation
Cancer Inflammation and Immunity, CRUK Manchester Institute.Issue Date
2021
Metadata
Show full item recordAbstract
Identifying strategies to improve the efficacy of immune checkpoint blockade (ICB) remains a major clinical need. Here, we show that therapeutically targeting the COX-2/PGE2/EP2-4 pathway with widely used non-steroidal and steroidal anti-inflammatory drugs synergized with ICB in mouse cancer models. We exploited a bilateral surgery model to distinguish responders from non-responders shortly following treatment and identified acute IFN-γ-driven transcriptional remodeling in responder mice, which was also associated with patient benefit to ICB. Monotherapy with COX-2 inhibitors or EP2-4 PGE2 receptor antagonists rapidly induced this response program and, in combination with ICB, increased the intratumoral accumulation of effector T cells. Treatment of patient-derived tumor fragments from multiple cancer types revealed a similar shift in the tumor inflammatory environment to favor T cell activation. Our findings establish the COX-2/PGE2/EP2-4 axis as an independent immune checkpoint and a readily translatable strategy to rapidly switch the tumor inflammatory profile from cold to hot.Citation
Pelly VS, Moeini A, Roelofsen LM, Bonavita E, Bell CR, Hutton C, et al. Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy. Cancer Discov. 2021 May 24;candisc.1815.2020.Journal
Cancer DiscoveryDOI
10.1158/2159-8290.Cd-20-1815PubMed ID
34031121Additional Links
https://dx.doi.org/10.1158/2159-8290.Cd-20-1815Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/2159-8290.Cd-20-1815
Scopus Count
Collections
Related articles
- Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
- Authors: Han X, Li H, Zhou D, Chen Z, Gu Z
- Issue date: 2020 Nov 17
- Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
- Authors: McAuliffe J, Chan HF, Noblecourt L, Ramirez-Valdez RA, Pereira-Almeida V, Zhou Y, Pollock E, Cappuccini F, Redchenko I, Hill AV, Leung CSK, Van den Eynde BJ
- Issue date: 2021 Sep
- Neoadjuvant immune checkpoint blockade triggers persistent and systemic T(reg) activation which blunts therapeutic efficacy against metastatic spread of breast tumors.
- Authors: Blomberg OS, Kos K, Spagnuolo L, Isaeva OI, Garner H, Wellenstein MD, Bakker N, Duits DEM, Kersten K, Klarenbeek S, Hau CS, Kaldenbach D, Raeven EAM, Vrijland K, Kok M, de Visser KE
- Issue date: 2023
- Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
- Authors: Pieper AA, Rakhmilevich AL, Spiegelman DV, Patel RB, Birstler J, Jin WJ, Carlson PM, Charych DH, Hank JA, Erbe AK, Overwijk WW, Morris ZS, Sondel PM
- Issue date: 2021 Jun
- Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
- Authors: Isaacs J, Anders C, McArthur H, Force J
- Issue date: 2021 Mar 20